AstraZeneca vaccine shows 95% effectiveness found in a recent study

The pharmaceutical company and the University of Oxford would receive approval from international bodies this week and it would be the third vaccine approved along with Moderna and Pfizer

The vaccine against Covid-19 currently being developed by the pharmaceutical company AstraZeneca and the University of Oxford showed 95 percent effectiveness, according to a study published on Saturday, December 26, by the British newspaper The Sunday Times.

According to the publication, the vaccine is expected to receive approval this week to be put into circulation on the market, since the director of the pharmaceutical company would have mentioned that during the trials the doses were effective against the highly transmissible strain of the coronavirus.

In this sense, the vaccine from AstraZeneca and the University of Oxford would become the third vaccine to receive approval from international regulatory bodies, since currently the vaccines from Pfizer and BioNtech have already been approved along with that of the Moderna company.

According to the British newspaper, the director of AstraZeneca, Pascal Soriot, revealed that the new data shows 95 percent effectiveness, which would put it on a par with the two vaccines that have already begun to be applied in countries such as the United States, Mexico, Spain and Canada.

It is worth mentioning that a week ago it was announced that AstraZeneca and the Russian laboratory that is responsible for developing the Spuntik V vaccine announced that they would carry out a series of joint clinical trials in which they would combine both vaccines.

“We announce a program of clinical trials to evaluate the safety and immunogenicity of the combination of ASD1222, developed by AstraZeneca and the University of Oxford, and Sputnik V, developed by the Gamaleya Research Institute,” the statement reads. It is announced that the tests will be carried out in groups with people over 18 years of age.

On the other hand, the newspaper The Telegraph assures that the vaccine would be launched from January 4 of next year, according to the plans of the United Kingdom minister, so it is expected to mitigate the infections that have already reached record figures and that, In addition, it has left great concern about a new mutation that scientists have identified as highly transmissible, since it is estimated that it is transmitted up to 70 percent faster than the original strain.

Leave a Reply

Your email address will not be published. Required fields are marked *